ARMOR1: Phase 1, Open Label, Dose Escalation Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer.

Trial Profile

ARMOR1: Phase 1, Open Label, Dose Escalation Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Galeterone (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ARMOR-1; ARMOR1
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Nov 2015 Pooled analysis results of ARMOR I and ARMOR II published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 04 Mar 2013 Results will be presented at the 2013 International Congress on Targeted Anticancer Therapies (TAT), according to a Tokai Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top